Two pharmacists figured out that oral phenylephrine doesn't work
Evidence that oral phenylephrine, a common “PE” ingredient in over-the-counter cold and sinus pills, is essentially ineffective has validated what many heavy allergy and cold sufferers say they observed for years. Commenters contrast phenylephrine with pseudoephedrine (Sudafed), which reliably works but was pushed behind the pharmacy counter because it can be used to make meth, and argue that this policy trade-off harmed patients without meaningfully reducing drug problems. The exchange broadens into concerns about how the FDA evaluates OTC efficacy, the role of anecdotes in challenging weak science, and the extent to which pharmacies knowingly profit from products that function as placebos.
Oral phenylephrine vs. other decongestants
- Strong consensus that oral phenylephrine does little or nothing for nasal congestion; many say this was obvious from personal use over years.
- Distinction emphasized: topical/nasal phenylephrine can work well; the US issue is specifically with oral formulations.
- Some report clear benefit from oral phenylephrine (especially “drying out” sinuses or helping post‑nasal drip), suggesting possible individual variation or mismeasured effects.
- A few cite studies indicating higher doses or co‑administration with acetaminophen may increase phenylephrine bioavailability, but current OTC doses are seen as ineffective.
Pseudoephedrine, meth laws, and access
- Pseudoephedrine is widely described as dramatically more effective; many recount switching back (behind‑the‑counter) and immediately noticing the difference.
- US and some other countries restrict pseudoephedrine due to its use in meth production; people debate whether this accomplished anything beyond shifting production to large‑scale operations.
- Some regions now require ID scans or even prescriptions; others (e.g., parts of Canada/Europe/Australia) allow easier access, which users envy.
Anecdotes, placebo, and scientific evidence
- Multiple comments stress that anecdotes aren’t proof but are crucial for hypothesis generation; others caution against over‑weighting them.
- Placebo effect is repeatedly invoked as an explanation for perceived benefit from phenylephrine and other OTC mixtures.
- Comparisons made to MSG sensitivity and other biologically complex, heterogeneous responses.
Regulators, pharmacies, and trust
- Heavy criticism of FDA and broader US regulatory culture: perceived as slow, under‑funded, captured by industry, and too willing to accept “generally recognized as safe and effective” status.
- Anger that pharmacies and manufacturers kept selling oral phenylephrine for ~20 years despite widespread professional skepticism.
- Some argue this is fraud that should trigger lawsuits or refunds; others note phenylephrine was “grandfathered” as safe without strong efficacy trials.
Alternatives and self‑management
- Many prefer: pseudoephedrine, xylometazoline or other nasal sprays (with warnings about rebound), corticosteroid sprays (e.g., fluticasone), antihistamines, saline rinses/neti pots, spicy food, or non‑US options.
- Some mention niche options like Ectoine sprays or zinc products; effectiveness is based on personal reports, not consensus.
- Several urge reading active‑ingredient labels, avoiding “PE” products, and buying generics with known effective ingredients.
Labeling, efficacy standards, and OTC market
- Suggestions include tiered labels: safety only, “plausible efficacy,” and “proven efficacy,” plus better batch testing.
- Others warn against over‑reliance on government or, conversely, against dismantling agencies and leaving safety to consumer reviews.
- Broader concern: many OTC cold/cough products (guaifenesin, dextromethorphan, some antihistamines for colds) may also have weak evidence; status is noted as unclear in the thread.